Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer

Published:2022-01 Issue: Volume:160 Page:227-234
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mizugaki Hidenori,Oizumi Satoshi,Fujita Yuka,Harada Toshiyuki,Nakahara Yoshiro,Takashina Taichi,Ko Ryo,Watanabe Kageaki^ORCID,Hotta Takamasa,Minemura Hiroyuki^ORCID,Saeki Sho,Asahina Hajime^ORCID,Nakamura Keiichi,Nakamura Hiromi,Hosoda Fumie,Yagishita Shigehiro,Hamada Akinobu

Funder

Japan Agency for Medical Research and Development

Boehringer Ingelheim Japan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Magnitude, temporal trends and inequality in global burden of tracheal, bronchus and lung cancer: findings from the Global Burden of Disease Study 2017;Wang;BMJ Glob Health,2020

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

2. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP);Lung Cancer;2023-12

3. Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study;Therapeutic Advances in Medical Oncology;2023-01

4. Medical management of older patients with lung cancer;Japanese Journal of Clinical Oncology;2022-08-16

5. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group;Cancer Treatment and Research Communications;2022